Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Integrated incremental immunoreactive insulin and connecting peptide responses to an oral glucose load of 50 g and an "isoglycaemic" intravenous glucose infusion, respectively, were measured in 14 Type 2 (non-insulin-dependent) diabetic patients and 8 age- and weight-matched metabolically healthy control subjects. Differences between responses to oral and intravenous glucose administration are attributed to factors other than glucose itself (incretin effect). Despite higher glucose increases, immunoreactive insulin and connecting peptide responses after oral glucose were delayed in diabetic patients. Integrated responses were not significantly different between both groups. However, during "isoglycaemic" intravenous infusion, insulin and connecting peptide responses were greater in diabetic patients than in control subjects as a consequence of the higher glycaemic stimulus. The contribution of incretin factors to total insulin responses was 72.8 +/- 6.9% (100% = response to oral load) in control subjects and 36.0 +/- 8.8% in diabetic patients (p less than or equal to 0.05). The contribution to connecting peptide responses was 58.4 +/- 7.6% in control subjects and 7.6 +/- 14.5% (p less than or equal to 0.05) in diabetic patients. Ratios of integrated insulin to connecting peptide responses suggest a reduced (hepatic) insulin extraction in control subjects after oral as compared to intravenous glucose. This was not the case in diabetic patients. Immunoreactive gastric inhibitory polypeptide responses were not different between control subjects and diabetic patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is well-known that the incretin effect is weakened or no longer present in subjects with T2D, albeit more or less normal secretion of GIP e GLP-1 [16,17,18].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [16]
Experimental — accuracy not yet measuredIn the citing paper
“People with obesity and/or T2D have impaired incretin release ( Toft-Nielsen et al., 2001 ; Vilsbøll et al., 2001 ) and/or function ( Nauck et al., 1986 ; Muscelli et al., 2008 )”
From Pharmacologic inhibition of somatostatin receptor 2 to restore glucagon counterregulation in diabetes (2024) · cites this paper as Nauck et al., 1986
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917 · cited 2×
“Thus the study of Perley and Kipnis [ 10 ] from 1967 does not - in the absence of C-peptide measurements - allow final conclusions about the incretin effect in Type 2 diabetic patients.”
BackgroundSeltzer, H. S., Allen, E. W., Herron, A. L., & Brennan, M. T. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105534 · Cited by 883
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 5×
“In healthy young subjects, a clear dose-dependency of incretin effects after oral glucose has been observed [6].”
BackgroundResultInfluentialSelf-citationRadioimmunological determination of human C-peptide in serum
Heding, L. G. (1975) · Diabetologia · doi:10.1007/bf01222104 · Cited by 830
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731 · cited 1×
“Insulin secretion after an oral glucose load is due to stimulation of the pancreatic B cell by elevation of the plasma glucose level and, in addition, by incretin factors (gastrointestinal hormones and possibly nerves) which potentiate the secretory response to hyperglycaemia alone [1, 2].”
BackgroundSelf-citationThe Effect of Insulin Treatment on Insulin Secretion and Insulin Action in Type II Diabetes Mellitus
Garvey, W. T., Olefsky, J. M., Griffin, J., Hamman, R. F., & Kolterman, O. G. (1985) · Diabetes · doi:10.2337/diab.34.3.222 · Cited by 488 · cited 1×
“Arguing against this explanation, intravenous isoproterenol [36] or glucagon [ 37 ] enhanced, rather than diminished, additional B cell secretory responses in Type 2 diabetic patients when plasma glucose levels had been elevated by glucose infusion up to the range employed in our study.”
ResultC-Peptide as a Measure of the Secretion and Hepatic Extraction of Insulin: Pitfalls and Limitations
Polonsky, K. S., & Rubenstein, A. H. (1984) · Diabetes · doi:10.2337/diab.33.5.486 · Cited by 476 · cited 3×
“This conclusion must, however, remain speculative because of reservations regarding the "insulin to C-peptide ratio method" for estimating changes in (hepatic) insulin extraction [ 33 ].”
BackgroundMethodInfluentialTHE PLASMA INSULIN RESPONSE TO GLUCOSE INFUSION IN HEALTHY SUBJECTS AND IN DIABETES MELLITUS
Cerasi, E., & Luft, R. (1967) · Acta Endocrinologica · doi:10.1530/acta.0.0550278 · Cited by 371 · cited 2×
“The markedly reduced incretin effect found in our group with a more severe degree of Type 2 diabetes may simply be an expression of their impaired capacity to secrete insulin at an adequate rate [3, 4 ]. The glycaemic stimulus with plasma glucose values of -17mmol/1 (300mg/dl) may already have led to maximal B cell st…”
BackgroundUnger, R. H. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.1969.00300130043007 · Cited by 371 · cited 1×
“Insulin secretion after an oral glucose load is due to stimulation of the pancreatic B cell by elevation of the plasma glucose level and, in addition, by incretin factors (gastrointestinal hormones and possibly nerves) which potentiate the secretory response to hyperglycaemia alone [1, 2 ].”
Background
Research works printed but not linked: 4
- Bloom SR (1975) GIP in diabetes (abstract). Diabetologia 11: 334
- WHO Expert Committee on Diabetes Mellitus, Second Report, Technical Report Series 646, WHO, Geneva, 1980
- Madison LL, Kaplan N (1958) The hepatic binding of I-131 labeled insulin in human subjects during a single transhepatic circulation. J Lab Clin Med 52: 927–932
- Ross SA, Brown JC, Dupre J (1974) Effects of Gastric Inhibitory Polypeptide on endocrine pancreas in normal and diabetic subjects. Diabetologia 10: 384 (Abstract)
Cited by
Items 801–900 of 1,001
The physiologic role of incretin hormones: clinical applications.
Cefalu, W. T. (2010) · PubMed · Cited by 10
Shen, H.-Q., Roth, M., & Peterson, R. G. (1998) · Metabolism · doi:10.1016/s0026-0495(98)90275-x · Cited by 11
Control of Glucose Homeostasis by Incretin Hormones
Perfetti, R., Brown, T. A., Velikina, R., & Busselen, S. (1999) · Diabetes Technology & Therapeutics · doi:10.1089/152091599317215 · Cited by 12
Brown, A., Mellor, D., Makaronidis, J., Shuttlewood, E., Miras, A. D., & Pournaras, D. J. (2024) · Nutrition Bulletin · doi:10.1111/nbu.12700 · Cited by 9
Krishnan, A., Suryanarayanan, S., & Mansi, I. A. (2024) · Journal of Pharmacy Technology · doi:10.1177/87551225241266773 · Cited by 9
Cardiovascular effects of tirzepatide
Sumithran, P., Russell, A. W., & Zoungas, S. (2025) · Journal of Endocrinology · doi:10.1530/joe-24-0259 · Cited by 12
Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide
Odigwe, C. I., Mulyala, R. R., Malik, H., Ruiz, B., Riad, M., Sayiadeh, M. A., Honganur, S., Parks, A., Rahman, M. U., & Lakkis, N. M. (2025) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2025.100518 · Cited by 17
López‐Cano, C., Santos, M. D., Sánchez, E., Martí, R., Bueno, M., Gutiérrez-Carrasquilla, L., & Lecube, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-07250-z · Cited by 10
Anderson, J. E., Gavin, J. R., Kruger, D. F., & Miller, E. M. (2022) · Clinical Diabetes · doi:10.2337/cd22-0020 · Cited by 10
A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment
Subramanian, V., Bagger, J. I., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.911616 · Cited by 10
Zibar, K., Čuča, J. K., Blaslov, K., Bulum, T., & Duvnjak, L. S. (2014) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563214544709 · Cited by 12
“METHODS: The cross-sectional study included 30 C-peptide negative T1DM patients, median age 37 years (20-59), the disease duration 22 years (3-45), and 10 healthy controls, median age 30 years (27-47).”
BackgroundMethodInfluentialThe effect of 8 days of strict bed rest on the incretin effect in healthy volunteers
Nielsen, S. T., Harder-Lauridsen, N. M., Benatti, F. B., Wedell‐Neergaard, A., Lyngbæk, M. P. P., Møller, K., Pedersen, B. K., & Krogh‐Madsen, R. (2015) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00821.2015 · Cited by 10
Postprandial glucose, insulin and incretin responses to different carbohydrate tolerance tests
Deng, Y., Zhang, Y., Zheng, S., Hong, J., Wang, C., Liu, T., Sun, Z., Gu, W., Gu, Y., Shi, J., et al. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12245 · Cited by 9
Impact of Newer Medications for Type 2 Diabetes on Body Weight
Pedersen, S. D. (2013) · Current Obesity Reports · doi:10.1007/s13679-012-0045-4 · Cited by 10
“There is additionally an element of impairment of the beta cell insulin secretory response to GLP-1 in type 2 diabetics [24].”
BackgroundEmerging role of insulin with incretin therapies for management of type 2 diabetes
Ahluwalia, R., & Vora, J. P. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0005-0 · Cited by 10
Incretin hormone receptors are required for normal beta cell development and function in female mice
Omar, B. A., Ahlkvist, L., Yamada, Y., Seino, Y., & Åhrén, B. (2016) · Peptides · doi:10.1016/j.peptides.2016.03.012 · Cited by 9
NUEVOS FÁRMACOS EN DIABETES MELLITUS
Aylwin, C. G. (2016) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2016.04.013 · Cited by 20
“Se ha demostrado que en pacientes con DM2 la respuesta al efecto incretina está alterada (14) como resultado de un severo defecto de la sensibilidad para el GIP en la célula Beta y de reducción en la secreción de GLP-1 inducida por alimentos (15).”
BackgroundNewmire, D. E., Rivas, E., Deemer, S. E., Willoughby, D. S., & Ben‐Ezra, V. (2019) · Nutrients · doi:10.3390/nu11112650 · Cited by 9
“It has been proposed that the incretin effect is responsible for driving ~50% to 70% of postprandial insulin response after carbohydrate (CHO) ingestion, in healthy individuals [22] while impaired in T2Ds [28].”
BackgroundTherapeutic intervention in the GLP‐1 pathway in Type 2 diabetes
Lévy, J. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01833e.x · Cited by 9
Herbach, N., Göke, B., Wolf, E., & Wanke, R. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2007.10.005 · Cited by 11
Abnormalities of Insulin Secretion and β‐Cell Defects in Type 2 Diabetes
Alsahli, M., & Gerich, J. E. (2010) · Wiley eBooks · doi:10.1002/9781444324808.ch10 · Cited by 18
Conflicting gastric inhibitory polypeptide data: possible causes
Alam, M. J., & Buchanan, K. D. (1993) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(93)90102-b · Cited by 12
Bailey, C. J., & Krentz, A. J. (2010) · Wiley eBooks · doi:10.1002/9781444324808.ch29 · Cited by 16
Sun, Y., Luo, Y., Xiang, C., Xie, C. H., Huang, W., Sun, Z., Jones, K. L., Horowitz, M., Rayner, C. K., Ma, J., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15626 · Cited by 9
“6,49 While insulin per se does not affect GE, 50 our study demonstrated for the first time that short-term insulin pump therapy slowed GE by >20% in this T2D cohort, suggesting a major modifying effect of this intervention on the factors that govern GE.”
Capozzi, M. E., Bouslov, D., Sargsyan, A., Chan, M. Y., Chen, A., Gray, S. M., Viloria, K., Bareja, A., Douros, J. D., Lewandowski, S. L., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci183741 · Cited by 10
“Another study reported that chronic hyperglycemia, mimicking T2D, induced the GLP-1R to switch from G α s to G α q as the proximal step leading to increased insulin secretion (21).”
InfluentialGrunberger, G. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12046 · Cited by 8
“This idea was replicated in 1986 by the work of Nauck et al.(4) By definition, incretin hormones are secreted after nutrient ingestion and stimulate insulin secretion at the”
MethodDedov, I. I., Yashkov, Y. I., & Ershova, E. V. (2012) · Obesity and metabolism · doi:10.14341/omet201223-10 · Cited by 14
New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
Gallwitz, B. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s4857 · Cited by 10
Liu, F., Wang, S., Guo, X., Ye, Z.-X., Zhang, H., & Li, Z. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i6.632 · Cited by 9
Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management
Rabbani, S. A., El‐Tanani, M., Matalka, I. I., Rangraze, I. R., Aljabali, A. A. A., Khan, M. A., & Tambuwala, M. M. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2395540 · Cited by 9
“A compelling body of evidences have reported decreased incretin effect in patients with T2D and obesity [16,17], which paved the way for restoration of this effect as a novel therapeutic strategy via development of GLP-1/GIP receptor agonist (RA)-based therapies for T2D and obesity.”
The role of glucagon-like peptides in osteosarcopenia
Tufail, E., Sanyal, S., Mithal, A., Sanyal, S., & Chattopadhyay, N. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0210 · Cited by 12
Gilliam‐Vigh, H., Ellegaard, A., Madsen, M. R., Lund, A., Jensen, B. A. H., Vilsbøll, T., Rigbolt, K. T. G., & Knop, F. K. (2025) · Gut · doi:10.1136/gutjnl-2024-334124 · Cited by 8
Wang, L., Wu, J., Cao, H., Chen, R., Zhang, N., Fu, J., Gao, B., Zhang, J., Hou, R., Tang, C.-W., et al. (2009) · Endocrine Pathology · doi:10.1007/s12022-009-9086-y · Cited by 8
“glucose secretion, immunoreactive insulin and related peptide responses after oral glucose were delayed in diabetic patients [ 3 ].”
BackgroundIncretins and Their Endocrine and Metabolic Functions
Seufert, J. (2017) · Endocrine development · doi:10.1159/000475730 · Cited by 9
Lauritzen, E. S., Støy, J., Bæch‐Laursen, C., Grarup, N., Jessen, N., Hansen, T. F., Møller, N., Hartmann, B., Holst, J. J., & Kampmann, U. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab521 · Cited by 11
Jørgensen, N. T., Erichsen, T. M., Jørgensen, M. B., Idorn, T., Feldt‐Rasmussen, B., Holst, J. J., Feldt‐Rasmussen, U., & Klose, M. (2023) · Pituitary · doi:10.1007/s11102-022-01297-x · Cited by 9
“Patients with type 2 diabetes mellitus have a markedly reduced incretin effect and GIGD compared to healthy individuals [32, 33], but impairment of the incretin effect and GIGD in non-diabetic patients with acromegaly has not previously been studied.”
BackgroundPathophysiology of Type 2 Diabetes
Kesavadev, J., Jawad, F., Deeb, A., Coetzee, A., Ansari, M., Shrestha, D., Somasundaram, N. P., & Kalra, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_9 · Cited by 10
Plasma Galectin-4 Levels Are Increased after Stroke in Mice and Humans
Vieira, J., Jujić, A., Matušková, H., Nilsson, P. M., Lindblad, U., Olsen, M. H., Duarte, J. M. N., Meißner, A., & Magnusson, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210064 · Cited by 8
Ownby, D. R. (1995) · Allergy · doi:10.1111/j.1398-9995.1995.tb04343.x · Cited by 8
Saglietti, G., Placentino, G., & Schellino, A. (2014) · Clinical Drug Investigation · doi:10.1007/s40261-014-0196-z · Cited by 8
“T2DM is a complex disease involving a reduction in insulin secretion, insulin resistance and significant reduction in the secretion of the main incretin hormone, glucagon-like peptide-1 (GLP-1), secreted by intestinal L cells in response to a meal [7]; this hormone has several important actions linked to carbohydrate…”
BackgroundZhang, Y., Chi, J., Wang, W., Hong, J., Gu, W., Wang, B., & Ning, G. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12175 · Cited by 8
Incretin-based therapies for type 2 diabetes mellitus in Asian patients: Analysis of clinical trials
Louisa, M., Takeuchi, M., Takeuchi, M., Nafrialdi, N., & Setiabudy, R. (2010) · Medical Journal of Indonesia · doi:10.13181/mji.v19i3.406 · Cited by 10
Roussel, M., Mathieu, J., & Dalle, S. (2016) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2015-0071 · Cited by 13
ASGE EndoVators Summit: Defining the role and value of endoscopic therapies in obesity management
Ryou, M. K., McQuaid, K. R., Thompson, C. C., Edmundowicz, S. A., Mergener, K., Dayyeh, B. A., Apovian, C. M., Burke, C. A., Chand, B., Chandraker, A. K., et al. (2017) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2017.08.004 · Cited by 9
“These lessons from surgery have led to the development of small-bowel devices intended to treat diabetes through GI hormonal changes (incretin effect).(60) Endobarrier (GI Dynamics, Boston, Mass, USA).”
BackgroundFrom Entero-Endocrine Cell Biology to Surgical Interventional Therapies for Type 2 Diabetes
Guimarães, M., Pereira, S. S., & Monteiro, M. P. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_480 · Cited by 9
Glucagon-like peptide 1 (GLP-1) and incretin mimetics for the treatment of diabetes
Nauck, M. A. (2005) · Practical Diabetes · doi:10.1002/pdi.801 · Cited by 8
Self-citationEvidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes
Schwartz, S. S. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2757 · Cited by 9
Nuevos agentes terapéuticos para la diabetes tipo 2
Puig‐Domingo, M., & Pellitero, S. (2014) · Medicina Clínica · doi:10.1016/j.medcli.2014.03.018 · Cited by 9
The multifaceted role of ATF4 in regulating glucose-stimulated insulin secretion
Sobajima, M., Miyake, M., Hamada, Y., Tsugawa, K., Oyadomari, M., Inoue, R., Shirakawa, J., Arima, H., & Oyadomari, S. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.04.038 · Cited by 8
GLP1: the early steps of a success story
Bakar, R. B. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00821-8 · Cited by 7
Pal, B., & Chattopadhyay, M. (2024) · Journal of Diabetology · doi:10.4103/jod.jod_117_23 · Cited by 8
Rees, T. A., Buttle, B., Tasma, Z., Yang, S.-H., Harris, P. W. R., & Walker, C. S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1463313 · Cited by 10
Feline Diabetes Is Associated with Deficits in Markers of Insulin Signaling in Peripheral Tissues
Patra, S., McMillan, C. J., Snead, E. R., Warren, A. L., Cosford, K., & Chelikani, P. K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313195 · Cited by 9
Glucagon-like peptide-1 agonists in the treatment of type 2 diabetes.
Edwards, C. (2013) · British journal of hospital medicine · doi:10.12968/hmed.2013.74.4.198 · Cited by 7
Incretin-Based Therapy for Type 2 Diabetes Mellitus: Pancreatic and Extrapancreatic Effects
Hartman, I., Rojas, E., & Rodríguez-Molina, D. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e318235f27d · Cited by 9
New avenues for the pharmacological management of type 2 diabetes: An update
Cuny, T., Guerci, B., & Cariou, B. (2012) · Annales d Endocrinologie · doi:10.1016/j.ando.2012.09.002 · Cited by 7
Hansen, M., Sonne, D. P., Mikkelsen, S. U., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001803 · Cited by 9
“INTRODUCTION Description of the condition Type 2 diabetes mellitus (T2DM) is a severe metabolic disease characterised by relative insulin deficiency, including defective insulin secretion and insulin resistance, inappropriate glucagon secretion and impaired incretin effect resulting in fasting and postprandial hypergl…”
BackgroundGhrelin: A New Incretin Enhancer Therapy?
DeMarco, V. G., & Sowers, J. R. (2015) · Diabetes · doi:10.2337/db14-1871 · Cited by 8
“Earlier studies showed that the incretin axis in individuals with type 2 diabetes mellitus (T2DM) is impaired (4,5), and this has led to the development of novel incretin-enhancing therapies, such as the stable (i.”
BackgroundAlshali, K. Z., & Karawagh, A. M. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.8.15800 · Cited by 7
Rathish, D., Senavirathna, I., Jayasumana, C., Agampodi, S. B., & Siribaddana, S. (2018) · Environmental Science and Pollution Research · doi:10.1007/s11356-018-3818-9 · Cited by 8
Incretins in fibrocalculous pancreatic diabetes: A unique subtype of pancreatogenic diabetes
Ghosh, I., Mukhopadhyay, P., Das, K., Beatrice, A., Mondal, S. A., Basu, M., Nargis, T., Pandit, K., Chakrabarti, P., & Ghosh, S. K. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13139 · Cited by 7
Mirzaei, F., Khodadadi, I., Majdoub, N., Vafaei, S. A., Tayebinia, H., & Oshaghi, E. A. (2022) · The Open Medicinal Chemistry Journal · doi:10.2174/18741045-v16-e2212130 · Cited by 7
Glucagon-Like Peptide-1 and Its Implications in Obesity
Hurtado-Carneiro, V., Roncero, I., Blázquez, E., Álvarez, E., & Sanz, C. (2013) · InTech eBooks · doi:10.5772/54221 · Cited by 9
“[33] first documented a reduced incretin effect in patients, with type 2 diabetes.”
BackgroundInfluentialPharmacology of GLP-1 agonists: describing the therapeutic potential to patients.
Spellman, C. (2011) · PubMed · Cited by 10
Chakraborty, S., Rendón-Ramírez, A., Ásgeirsson, B., Dutta, M., Ghosh, A. S., Oda, M., Venkatramani, R., Rao, B. J., Dandekar, A. M., & Goñi, F. M. (2015) · F1000Research · doi:10.12688/f1000research.2-286.v3 · Cited by 8
Åhrén, B. (2006) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000216964.28881.ba · Cited by 9
Sugunan, D., Nair, A. K., Kumar, H., & Gopalakrishnapillai, A. (2010) · BMC Medical Genetics · doi:10.1186/1471-2350-11-118 · Cited by 8
“Though there is no conclusive evidence in the literature suggesting an altered expression of GIP, it has been shown that, in type 2 diabetes, the overall incretin effect is reduced and this was mainly attributed to altered functioning of GIP [25,26].”
BackgroundNeue orale Antidiabetika: Klinische Perspektiven
Fischer, S., & Bornstein, S. R. (2008) · Der Internist · doi:10.1007/s00108-007-1999-2 · Cited by 10
“Bei Typ-2-Diabetikern ist dieser Inkretineffekt deutlich reduziert und damit die Differenz der Insulinspiegel nach oraler und intravenöser Glukosegabe wesentlich geringer [14].”
Yu, S. H., Cho, B., Lee, Y., Kim, E., Choi, S. H., Lim, S. K., Yi, K. H., Park, Y. J., Park, K. S., & Jang, H. C. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.1.58 · Cited by 7
“The decreasing incretin effect of insulin secretion in type 2 diabetes was known, while the one of main pathogenesis pathway of type 2 diabetes, insulin secretion impairment is sometimes assumed to be an incretin disorder [8,10].”
BackgroundPathogenesis of Type 2 Diabetes Mellitus
Kalin, M. F., Goncalves, M., & Fonseca, V. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-20797-1_13-1 · Cited by 10
Tanaka, K., Okada, Y., Mori, H., Miyazaki, M., Kuno, F., Sonoda, S., Sugai, K., Hajime, M., Kurozumi, A., Narisawa, M., et al. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0341 · Cited by 7
Effects of active farnesoid X receptor on GLUTag enteroendocrine L cells
Niss, K., Jakobsson, M. E., Westergaard, D., Belling, K., Olsen, J. V., & Brunak, S. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.110923 · Cited by 8
“A reduction of the incretin-effect has pathological implications as seen in type 2 diabetes (T2D) where a decrease in meal-induced GLP-1 secretion can, in part, explain the insufficient insulin secretion (Holst, 2007; Nauck et al., 1986).”
BackgroundIncretins in the Therapy of Diabetic Kidney Disease
Przezak, A., Bielka, W., & Pawlik, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212312 · Cited by 7
Shah, A. M., PRASAD, M. A., Mark, V., Holst, J. J., & Laferrère, B. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14793 · Cited by 7
Tajima, K., Shirakawa, J., Togashi, Y., Inoue, H., Sato, K., Orime, K., Ito, Y., Kaji, M., Sakamoto, E., Nakamura, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064633 · Cited by 8
“markedly reduced in patients with type 2 diabetes [3].”
BackgroundChowdhury, S., Wang, S., Dunai, J., Kilpatrick, R., Oestricker, L. Z., Wallendorf, M., Patterson, B. W., Reeds, D. N., & Wice, B. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156852 · Cited by 7
Gosselé, K. A., Opitz, L., Arnold, M., Simon, E., Neubauer, H., & Wolfrum, S. (2019) · Peptides · doi:10.1016/j.peptides.2019.01.001 · Cited by 8
Gene x Gene Interactions Highlight the Role of Incretin Resistance for Insulin Secretion
Jaghutriz, B. A., Heni, M., Lutz, S. Z., Fritsche, L., Machicao, F. E., Staiger, H., Peter, A., Häring, H., Fritsche, A., & Wagner, R. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00072 · Cited by 7
“Among incretins, particularly GLP-1 and GIP are key factors of diet induced stimulation of insulin secretion accounting for up to 70% of postprandial insulin secretion (13).”
BackgroundPathogenesis of Type 2 Diabetes Mellitus
Kalin, M. F., Goncalves, M., John‐Kalarickal, J., & Fonseca, V. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-20797-1_13-2 · Cited by 11
Åhrén, B. (2009) · Insulin · doi:10.1016/s1557-0843(09)80004-3 · Cited by 7
Expanding Treatment Options for Type 2 Diabetes The Old and the New
Pratley, R. E. (2009) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721709331522 · Cited by 8
“Impairment of the incretin system is another important metabolic defect of type 2 diabetes.(5,12) The incretin effect can be defined as the augmentation in insulin secretion that occurs in response to an oral as opposed to an isoglycemic intravenous glucose challenge (Figure 1).”
BackgroundSitagliptin — enhancing incretin action
Campbell, I. W., & Day, C. (2007) · The British Journal of Diabetes · doi:10.1177/14746514070070030601 · Cited by 7
Jones, I. R., Owens, D. R., Vora, J. P., Luzio, S. D., & Hayes, T. M. (1989) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(89)90014-4 · Cited by 7
The Evidence for Achieving Glycemic Control With Incretin Mimetics
Drucker, D. J. (2006) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721706287652 · Cited by 7
“Although individuals with type 2 diabetes show an impairment in GLP-1 secretion, the ability of GLP-1 to exert effects on glucose metabolism and weight is preserved.(17,18) Research has demonstrated that increasing exposure to GLP-1 affects a number of different targets: it normalizes glucose levels, promotes glucose-…”
BackgroundIncretin Hormones and the Up-Regulation of Insulin Secretion in Insulin Resistance
Åhrén, B. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1420 · Cited by 7
“It is now well documented that the incretin effect is reduced in type 2 diabetes (3).”
BackgroundPhysiology and pathophysiology of GIP: A review
Krarup, T., & Groop, P. (1991) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365519109104567 · Cited by 8
Assessment of the incretin effect in healthy subjects: concordance between clamp and OGTT methods
Aulinger, B. A., & D’Alessio, D. A. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00104.2022 · Cited by 6
The Enteric Neuronal Circuitry: A Key Ignored Player in Nutrient Sensing Along the Gut–Brain Axis
Nikolla, E., Grandberry, A., Jamerson, D., Flynn, C. R., & Sundaresan, S. (2025) · The FASEB Journal · doi:10.1096/fj.202500220rr · Cited by 7
“However, in subjects with T2D, the incretin effect is markedly reduced, as evidenced by blunted postprandial insulin release and subsequent poor glycemic control and impaired satiety signaling [155].”
Ismail, A., Amer, M. S., & Tawheed, A. (2025) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v16.i3.107148 · Cited by 7
Jalleh, R. J., Wu, T., Umapathysivam, M. M., Young, R. L., Jones, K. L., Marathe, C. S., Rayner, C. K., Plummer, M. P., & Horowitz, M. (2026) · Physiological Reviews · doi:10.1152/physrev.00009.2025 · Cited by 6
Duodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetes
Bailey, C. J., & Flatt, P. R. (2024) · Peptides · doi:10.1016/j.peptides.2024.171168 · Cited by 6
Glucagon-like Peptide-1 Receptor Agonists in the Management of Diabetic Retinopathy
Samanta, A., Bordbar, D. D., Weng, C. Y., & Chancellor, J. R. (2024) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000541 · Cited by 7
“5,6 Despite this, high levels of exogenously administered GLP-1 demonstrate an ability to overcome β -cell dysfunction and improve glucose responsiveness to normal levels.”
Traitement du diabète de type 2 : l’exénatide à libération prolongée
Guerci, B., & Sauvanet, J.-P. (2014) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(14)70734-5 · Cited by 6
DPP-4 Inhibition and the Known Unknown
Horowitz, M., Wu, T., Deane, A. M., Jones, K. L., & Rayner, C. K. (2016) · Diabetes · doi:10.2337/dbi16-0023 · Cited by 6
Takayanagi, R., Uchida, T., Kimura, K., & Yamada, Y. (2018) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00237 · Cited by 6
Fotheringham, A. K., Bagger, J. I., Borg, D. J., McCarthy, D. A., Holst, J. J., Vilsbøll, T., Knop, F. K., & Forbes, J. M. (2020) · Nutrients · doi:10.3390/nu12102928 · Cited by 6
“In type 2 diabetes, the incretin effect is impaired, thereby exacerbating hyperglycaemia [11,12].”
BackgroundBayesian analysis of Glucose dynamics during the Oral Glucose Tolerance Test (OGTT)
Flores-Argüedas, H., Centro de Investigación en Matemáticas, A. C., & Capistrán, M. A. (2021) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2021235 · Cited by 6
“Incretin effect is reduced or even vanished in diabetic patiens, [8,9].”
BackgroundIntervention with Therapeutic Agents, Understanding the Path to Remission to Type 2 Diabetes
Hao, S., Umpierrez, G. E., & Vellanki, P. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.07.004 · Cited by 6
Dow, R. L., & Kreutter, D. K. (1995) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60930-6 · Cited by 6
Puddu, A., Sanguineti, R., Montecucco, F., & Viviani, G. L. (2015) · Journal of Diabetes Research · doi:10.1155/2015/326359 · Cited by 7
Metadata
- Authors
- Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W.
- ORCID
- Nauck, M.
- Venue
- Diabetologia
- Published
- 1986-01
- Volume
- 29
- Issue
- 1
- Pages
- 46-52
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2054564814
- Cited by
- 1,307
- References
- 40
- Citations by year
- 2026: 20 · 2025: 34 · 2024: 45 · 2023: 38 · 2022: 53 · 2021: 46 · 2020: 44 · 2019: 60 · 2018: 41 · 2017: 47 · 2016: 65 · 2015: 63 · 2014: 82 · 2013: 86 · 2012: 74
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, incretin effect, insulin secretion, C-peptide, glucose-dependent insulinotropic polypeptide, oral glucose tolerance, intravenous glucose infusion, hepatic insulin extraction, immunoreactive insulin
- MeSH terms
- Adult, Aged, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Female, Gastric Inhibitory Polypeptide, Glucose, Glucose Tolerance Test, Humans, Infusions, Parenteral, Insulin, Male, Middle Aged, Pancreas
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.